BioInvent International AB (publ)
BINV
Rank in Stocks
#26526
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated... BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
Share Price
$0.30046698
Last synced: 2026-11-09
Market Cap
$19.77M
Change (1 day)
19.36%
Change (1 year)
-90.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioInvent International AB (publ) (BINV)
Category
Healthcare
EPS for BioInvent International AB (publ) (BINV)
EPS as of September 2026 TTM: $-0.75
According to BioInvent International AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.75. At the end of 2025 the company had an EPS of $-0.55, an increase over its 2024 EPS of $-0.59.
EPS history for BioInvent International AB (publ) from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.75 | 35.80% |
| 2025 | $-0.55 | -7.38% |
| 2024 | $-0.59 | 18.99% |
| 2023 | $-0.50 | 844.21% |
| 2022 | $-0.05 | -90.74% |
| 2021 | $-0.57 | 76.14% |
| 2020 | $-0.32 | -59.94% |
| 2019 | $-0.81 | -20.55% |
| 2018 | $-1.02 | 2.73% |
| 2017 | $-0.99 | 45.28% |
| 2016 | $-0.68 | -64.14% |
| 2015 | $-1.90 | 23.28% |
| 2014 | $-1.54 | 109.50% |
| 2013 | $-0.73 | -90.50% |
| 2012 | $-7.73 | 166.25% |
| 2011 | $-2.90 | -52.01% |
| 2010 | $-6.05 | -28.97% |
| 2009 | $-8.52 | -1,294.63% |
| 2008 | $0.71 | -176.25% |
| 2007 | $-0.94 | -85.50% |
| 2006 | $-6.45 | -39.32% |
| 2005 | $-10.63 | 25.71% |
| 2004 | $-8.46 | -211.82% |
| 2003 | $7.56 | 130.86% |
| 2002 | $3.28 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,196.67% |
US
|
|
| $-7.07 | 846.58% |
US
|
|
| $-5.29 | 608.26% |
AU
|
|
| $12.88 | -1,824.47% |
BE
|
|
| $21.56 | -2,986.60% |
NL
|
Questions about BioInvent International AB (publ)'s earnings per share (EPS)
What is BioInvent International AB (publ)'s earnings per share (EPS)?
BioInvent International AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.75, as of Sep 2026.
What was BioInvent International AB (publ)'s earnings per share (EPS) in 2025?
In 2025, BioInvent International AB (publ)'s earnings per share (EPS) was $-0.55, compared with $-0.59 in 2024.
How has BioInvent International AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioInvent International AB (publ)'s earnings per share (EPS) was highest in 2022 ($-0.05) and lowest in 2024 ($-0.59).
How does BioInvent International AB (publ)'s earnings per share (EPS) compare with similar companies?
BioInvent International AB (publ)'s earnings per share (EPS) ($-0.75) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.